Skip to main content
Download PDF

Therapeutic effect of Echinococcus granulosus cyst fluid on bacterial sepsis in mice

Parasites & Vectors volume 16, Article number: 450 (2023) Cite this article

Abstract

Background

The primary pathophysiological process of sepsis is to stimulate a massive release of inflammatory mediators to trigger systemic inflammatory response syndrome (SIRS), the major cause of multi-organ dysfunction and death. Like other helminths, Echinococcus granulosus induces host immunomodulation. We sought to determine whether E. granulosus cyst fluid (EgCF) displays a therapeutic effect on sepsis-induced inflammation and tissue damage in a mouse model.

Methods

The anti-inflammatory effects of EgCF were determined by in vitro culture with bone marrow-derived macrophages (BMDMs) and in vivo treatment of BALB/C mice with cecal ligation and puncture (CLP)-induced sepsis. The macrophage phenotypes were determined by flow cytometry, and the levels of cytokines in cell supernatants or in sera of mice were measured (ELISA). The therapeutic effect of EgCF on sepsis was evaluated by observing the survival rates of mice for 72 h after CLP, and the pathological injury to the liver, kidney, and lung was measured under a microscope. The expression of TLR-2/MyD88 in tissues was measured by western blot to determine whether TLR-2/MyD88 is involved in the sepsis-induced inflammatory signaling pathway.

Results

In vitro culture with BMDMs showed that EgCF promoted macrophage polarization to M2 type and inhibited lipopolysaccharide (LPS)-induced M1 macrophages. EgCF treatment provided significant therapeutic effects on CLP-induced sepsis in mice, with increased survival rates and alleviation of tissue injury. The EgCF conferred therapeutic efficacy was associated with upregulated anti-inflammatory cytokines (IL-10 and TGF-β) and reduced pro-inflammatory cytokines (TNF-α and INF-γ). Treatment with EgCF induced Arg-1-expressed M2, and inhibited iNOS-expressed M1 macrophages. The expression of TLR-2 and MyD88 in EgCF-treated mice was reduced.

Conclusions

The results demonstrated that EgCF confers a therapeutic effect on sepsis by inhibiting the production of pro-inflammatory cytokines and inducing regulatory cytokines. The anti-inflammatory effect of EgCF is carried out possibly through inducing macrophage polarization from pro-inflammatory M1 to regulatory M2 phenotype to reduce excessive inflammation of sepsis and subsequent multi-organ damage. The role of EgCF in regulating macrophage polarization may be achieved by inhibiting the TLR2/MyD88 signaling pathway.

Graphical Abstract

Background

Sepsis is the overwhelming immune response to serious bacterial infection that can lead to tissue damage, organ failure, and death [1, 2]. It is a life-threatening condition and one of the most severe complications in patients with acute infections [3, 4]. A conservative estimate of 48.9 million cases of sepsis and about 11 million deaths from sepsis worldwide was reported as of 2017 [5]. Therefore, a better understanding of the pathogenesis of sepsis and the search for a better treatment have become essential for reducing its mortality. Recent studies have shown that the essence of sepsis is an imbalanced immune response between pro-inflammatory and anti-inflammatory mechanisms [6, 7]. In sepsis, when macrophages and other innate immune cells detect bacterial pathogens or are activated by bacterial endotoxin, they release many pro-inflammatory cytokines to produce inflammatory cytokine storms called systemic inflammatory response syndrome (SIRS) to eliminate and clear infectious organisms [8, 9]. The inflammation reactions damage the structure and function of vital organs such as the kidney, liver, and lung [10,11,12,13] and even lead to multiple organ dysfunction and failure. Simultaneously, some immune cells can be activated to unleash an anti-inflammatory response characterized by the release of anti-inflammatory cytokines. This is called compensatory anti-inflammatory response syndrome (CARS), and its purpose is to restore homeostasis and reduce immunopathological damage; however, it may cause immunosuppression with delayed pathogen clearing [14]. Therefore, balancing the inflammatory and anti-inflammatory responses has become the focus of treating sepsis.

Macrophages, as important intrinsic immune cells during inflammatory response, play a crucial role in the immune responses and become the central target cells in the treatment of sepsis [15,16,17]. The heterogeneity of macrophages leads to a diversity of functions. Activated macrophages can exhibit different phenotypes and exert different pro- or anti-inflammatory effects depending on the surrounding environmental signals [18]. M1-type macrophages are typically characterized by high levels of oxidative metabolites (reactive oxygen species and NO) and pro-inflammatory cytokines (tumor necrosis factor alpha [TNF-α] and interleukin [IL]-6), which amplify the inflammatory cytokine storm and aggravate sepsis [19]. In contrast, M2-type macrophages produce high levels of Arg-1, CD206, IL-10, and transforming growth factor beta (TGF-β), which play an immunomodulatory role and have a therapeutic effect on sepsis [20]. The ratio of M1-type to M2-type macrophages influences the regression of sepsis [21].

Toll-like receptors (TLRs), a family of receptors expressed on the membrane of innate immune cells associated with cell recognition [22, 23], are intermediate in the generation of a persistent systemic “inflammatory waterfall” and closely associated with the development of sepsis [24]. Upon pathogen recognition through TLR4 or TLR2, the MyD88 signal pathway is stimulated and mediates inflammatory immune responses [25] to clear the invader pathogens and induce immunopathology as well. Knockdown of MyD88 was found to reduce lipopolysaccharide (LPS)-induced lung injury and fibrosis [26]. Even though both TLR2 and TLR4 are major receptors of gram-negative bacteria-produced LPS [27], in our pre-experiment screening test, we only found that the TLR2/MyD88 signaling pathway was significantly induced by LPS. Uncontrolled TLR2/MyD88 signal activation may cause excessive release of inflammatory mediators, leading to severe inflammatory reactions and causing tissue damage [28]. Therefore, the TLR2/MyD88 signaling pathway can serve as an essential marker for the severity of sepsis and treatment efficacy.

In 1989, Strachan [29] proposed the “hygiene hypothesis” based on the observed correlation between cleanliness of helminth infection and increased autoimmune and allergic diseases. Further evidence has shown that helminths secrete a variety of proteins that play a role in modulating the host immune response to reduce immune attack on the parasites as a survival strategy while reducing the hypersensitivity status of the host immune system during some autoimmune diseases or inflammatory diseases. Based on the immunomodulatory functions of helminth infection or helminth-produced proteins, the helminth therapy or the worm-derived products of autoimmune or inflammatory diseases (e.g., excretory/secretory products [SPs]), extracellular vesicles [EVs], recombinant protein molecules) have been successfully applied to experimentally treat some autoimmune or inflammatory diseases [30,31,32,33,34,35]. The immunomodulation of helminth-derived proteins includes regulating the function of antigen-presenting cells, activating Treg cells to promote anti-inflammatory factors such as TGF-β and IL-10, and stimulating M2 macrophage polarization [36,37,38,39,40].

Echinococcus granulosus is a parasitic tapeworm found in humans and animals, and its larvae can survive in human tissue (liver or lung) as hydatid cysts for up to 53 years [41], possibly by releasing immunomodulatory proteins to activate host regulatory network elements. Animal experiments have confirmed the therapeutic effect of E. granulosus infection on intestinal inflammation and asthma [42, 43]. However, the application of live helminth infection is risky to human health and not acceptable [44, 45]. Instead, helminth-derived proteins can avoid the risk of helminth infection and produce similar anti-inflammatory effects [32]. Our previous study showed that antigen B secreted by E. granulosus could modulate host immune responses to inhibit Th17 and promote Treg differentiation, thus alleviating the airway inflammatory response to asthma [46]. In the present study, we sought to determine whether E. granulosus cyst fluid (EgCF) is able to exert a similar immunomodulatory effect on sepsis and whether macrophages are involved in the anti-inflammatory differentiation during treatment of sepsis.

Methods

Preparation of EgCF

Fertile hydatid cysts were surgically removed from an infected patient in Xingjiang, China. The patient signed informed consent form. The EgCF was collected by centrifuging the fluid collected from the cysts at 12,000×g for 30 min at 4 °C to remove protoscolices and other worm materials. The potentially contaminated endotoxin in EgCF was removed using a ToxOut™ High Capacity Endotoxin Removal Kit (BioVision, Palo Alto, CA, USA), and the residual endotoxin was assessed using a ToxinSensor™ Chromogenic Limulus Amebocyte Lysate (LAL) Endotoxin Assay Kit (GenScript Biotechnology, Nanjing, China). The protein concentration in the collected EgCF was determined using a bicinchoninic acid (BCA) protein assay kit (Biosharp, Hefei, China).

Animals

Specific-pathogen-free male BALB/c mice, 6–8 weeks old, were obtained from Custer Laboratory Animal Center, Suzhou. All animal experiments were carried out in accordance with the regulations for the administration of Affairs Concerning Experimental Animals in China using the approved protocol (approval no. LAEC-2022-413).

Preparation and induction of mouse bone marrow-derived macrophages (BMDMs)

Donor mice were sacrificed by cervical dislocation, and the femur and tibia were recovered and washed twice with PBS. The bone marrow cavities were rinsed out with an incomplete Dulbecco's modified Eagle medium (DMEM; Thermo Fisher, MA, USA), and the rinse solution was filtered with a 200-mesh screen to remove fragments. The cells in the rinse solution were spun down and resuspended in a complete DMEM medium containing 10% fetal bovine serum (FBS) and 1× penicillin (100 U/ml)/streptomycin (100 μg/ml). The cells were cultured in complete DMEM supplemented with 20 ng/ml mouse macrophage colony-stimulating factor (M-CSF) (R&D Systems, MN, USA) for 7 days. The mature BMDMs were confirmed using flow cytometry with markers of CD11b+F4/80+.

Effect of EgCF on macrophage polarization in vitro

The mature BMDMs collected from the above culture were divided into five groups: (i) incubated with DMEM only (DMEM group), (ii) incubated with LPS (100 ng/ml) (LPS group), (iii) incubated with IL-4 (20 ng/ml) (IL-4 group), (iv) co-incubated with LPS (100 ng/ml) and EgCF (1 ug/ml) (EgCF + LPS group), and (v) incubated with EgCF only (1 ug/ml) (EgCF group). After being cultured for 24 h, the cells were collected for measuring CD86 and CD206 expression on the surface using flow cytometry, and the culture supernatant was collected for measuring the levels of TNF-α, interferon gamma (IFN-γ), TGF-β, and IL-10 using an enzyme-linked immunosorbent assay (ELISA) kit with specific antibodies (Dakewe Biotech, Beijing, China).

Analysis of macrophage polarization by flow cytometry

The collected BMDM cells were first treated with Fixable Viability Dye eFluor 510 (BioLegend, Inc., San Diego, CA, USA) for 10 min to differentiate live/dead cells. After being blocked with Fc receptor blocker (BioLegend, Inc., USA) for 10 min, the cells were incubated with FITC-anti-F4/80, BV605-anti-CD11b, and APC-anti-CD86 antibodies (BioLegend, Inc., USA) for surface marker staining for 25 min. For staining CD206, the cells were fixed and permeabilized using a Thermo fixation/permeabilization kit (Thermo Fisher Scientific, USA), then stained with PE-anti-CD206 (BioLegend, Inc., USA) for 30 min. The flow cytometry for these staining cells was performed using a DxP Athena™ flow cytometer (Cytek Biosciences Inc., CA, USA). The isotype-matched immunoglobulins (BioLegend, Inc., USA) and fluorescence minus one (FMO) were used as controls for non-specific staining as a baseline.

Mouse model of sepsis induced by cecal ligation and puncture (CLP)

Based on previous publications, a clinically relevant septic rodent model was established by CLP as described previously [47]. Briefly, mice were fasted for 12 h with only access to water, then anesthetized under isoflurane inhalation. The abdominal cavity was opened and the cecum was tightly ligated with a 3.0 silk suture at 1.0 cm from the apex. The puncture was made with an 18-gauge needle to squeeze out a small amount of stool and gently return the punctured cecum to the abdomen. The opened abdominal cavity was sutured layer by layer. In the control group, only laparotomy was performed without ligation and perforation. The general condition and survival rate of mice were observed for up to 72 h.

Treatment of sepsis with EgCF

Eighty mice were randomly divided into five groups with 16 mice in each group. The first three groups of mice were treated with CLP; 30 min after the surgery, each group of 16 mice was treated intraperitoneally with 1 ug EgCF (CLP + EgCF), 0.3 mg/kg dexamethasone (CLP + DXM) or PBS only as control (CLP) in a total volume of 100 μl, respectively. As normal controls, the remaining two groups of mice were treated with the sham operation, and then treated with the same dose of EgCF (sham + EgCF) or PBS (sham). Six mice from each group were sacrificed 12 h after treatment, the blood was obtained to separate sera for measuring the levels of different cytokines, and the liver, kidney, and lung were collected for histopathological examination. The remaining 10 mice from each group were observed for 72 h to determine the survival rate.

Serological test for cytokine profile and biochemical markers of organ damage

Serological levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured to determine liver injury, and the levels of blood urea nitrogen (BUN) and creatinine (Cr) were measured to assess kidney injury induced by sepsis. The serological levels of pro-inflammatory cytokines (TNF-α, IFN-γ) and regulatory anti-inflammatory cytokines (IL-10, TGF-β) were detected by using the same ELISA kit mentioned above.

Histopathological changes in tissues of the liver, kidney, and lung

Liver, kidney, and lung were collected from six mice in each experimental group after being euthanized 12 h after treatment, and fixed in 4% paraformaldehyde. The tissue was cut into 5-mm sections and stained with hematoxylin–eosin (HE). The histological liver injury was determined according to the degree of liver cell cytoplasmic vacuolation, hepatic sinus congestion, and liver cell necrosis [48], and corresponding scores were evaluated based on the criteria listed in Table 1. Histological renal injury was assessed based on the degree of damaged tubules and atrophic glomerulus score [49], as shown in Table 2. Histological lung injury scores were determined based on alveolar hyperemia, alveolar edema, neutrophil filtration, and alveolar septum thickening [50], as shown in Table 3.

Table 1 Liver injury score parameters
Full size table
Table 2 Kidney injury score parameters
Full size table
Table 3 Lung injury score parameters
Full size table

Real-time quantitative polymerase chain reaction (qPCR)

Total RNA of the liver, kidney, and lung tissues was extracted using TRIzol Up (TransGen Biotech, China) and reverse-transcribed to complementary DNA (cDNA) using the EasyScript®One-Step gDNA Removal and cDNA (TransGen Biotech, China). The relative messenger RNA (mRNA) expression of macrophage polarization-related markers inducible nitric oxide synthase (iNOS; M1) and Arg-1 (M2) in tissues of the liver, kidney, and lung were determined using PerfectStart® Green qPCR SuperMix (TransGen Biotech, China) on a Roche LightCycler® 96 real-time PCR system (Roche Molecular Systems, Inc., Pleasanton, CA, USA). The relative mRNA expression was calculated by the formula 2−△△Cq compared with housekeeper gene GAPDH. The primers for molecules mentioned above were synthesized by Sangon Biotech (Shanghai, China).

Expression of TLR2 and MyD88 in liver, kidney, and lung tissues of mice by western blotting

The total protein of the liver, kidney, and lung was extracted and the concentration was measured using BCA (Biosharp, Hefei, China). The tissue samples were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fluoride (PVDF) membrane. The membrane was blocked with 5% skim milk for 2 h, then recognized by rabbit anti-MyD88 antibody (1:4000), rabbit anti-TLR2 antibody (1: 3000), or rabbit anti-β-actin antibody (1:5000) (all from Cell Signaling Technology, Danvers, MA, USA) overnight at 4 °C. Sheep anti-rabbit IgG-HRP (1:7000) (Biosharp, Heifei, China) was used as secondary antibody. Immunoreactive protein bands were visualized by enhanced chemiluminescence (Bio-Rad, Hercules, CA, USA). The relative expression levels of MyD88 and TLR-2 were determined by the ratio of the identified density to the β-actin density of the control.

Statistical analysis

Statistical analysis was performed using one-way analysis of variance (ANOVA) for multi-group comparisons using unpaired, two-tailed Student’s t-test with Bonferroni adjustment, or ANOVA for multiple comparisons using GraphPad Prism 6.0 software (GraphPad Software, Inc., La Jolla, CA, USA). All data were presented as the mean ± standard error of the mean (SEM). Kaplan–Meier survival analysis was used to compare the difference in survival rates among groups. P < 0.05 was considered statistically significant.

Results

Protein components of EgCF

After separation by SDS-PAGE, EgCF appeared as several major bands at approximately 25 kDa, 55 kDa, and 70 kDa. (Fig. 1).

Fig. 1
figure 1

SDS-PAGE analysis of EgCF. Total 40 μg of EgCF was separated by 12% polyacrylamide gel electrophoresis and stained with Coomassie blue

Full size image

EgCF promotes M2 macrophage polarization and inhibits LPS-induced M1 macrophages

Bone marrow cells were induced with M-CSF for 7 days, and maturity of BMDMs was confirmed by flow cytometry with F4/80+ and CD11b+ (Fig. 2a). More than 99.6% of BMDMs were F4/80+CD11b+, which was significantly higher than the group incubated with PBS only (t-test: t(8) = 32.62, P < 0.001).

Fig. 2
figure 2

EgCF stimulated BMDM differentiation to M2 macrophages. a The mature BMDMs were obtained by incubating mouse bone marrow cells (adherent) with M-CSF for 7 days, defined as CD11b+F4/80+ subpopulations using FACS. b Gating strategy on flow cytometry to differentiate dead cells and adhere cells and BMDMs labeled with CD11b+F4/80+. c The isotype-matched immunoglobulins were used as a control for non-specific staining as a baseline. d, e EgCF enhanced M2 macrophages under LPS-stimulating conditions. BMDMs were incubated with EgCF (1 ug/ml), LPS (100 ng/ml), IL-4 (20 ng/ml), EgCF + LPS, or DMEM, respectively, for 24 h. The M1 (CD86) and M2 (CD206) markers were detected using FACS. The results were shown as the mean ± SEM for each group (n = 6). *P < 0.05, **P < 0.01, ***P < 0.001

Full size image

To investigate the effect of EgCF on macrophage polarization, the mature BMDMs were incubated with EgCF for 24 h and CD86 (M1) and CD206 (M2) were measured (Fig. 2b). The flow cytometry results showed that EgCF significantly induced F4/80+CD11b+CD206+ (M2) macrophages while it slightly induced (M1) macrophages (Fig. 2b). As positive controls, LPS strongly stimulated F4/80+CD11b+CD86+ macrophages (M1) and IL-4 stimulated F4/80+CD11b+CD206+ macrophages (M2) relative to DMEM plain medium control (ANOVA: F(4, 25) = 278.39, P < 0.0001 for the former and F(4, 25) = 278.39, P < 0.0001 for the latter) (Fig. 2d, e). Interestingly, under continuing stimulation of LPS, a similar situation as sepsis condition, EgCF still has the ability to reduce M1 (F4/80+CD11b+CD86+) and boost M2 (F4/80+CD11b+CD206+) macrophages (Fig. 2d, e).

EgCF inhibits pro-inflammatory cytokines and stimulated regulatory cytokines secreted by LPS-stimulated macrophages

The levels of different types of cytokines in the BMDM culture supernatant were measured by enzyme-linked immunosorbent assay (ELISA). The results showed that LPS-stimulated macrophages secreted high levels of pro-inflammatory cytokines TNF-α and IFN-γ relative to the culture with plain DMEM medium (ANOVA: F(4, 24) = 290.00, P < 0.0001; F(4, 20) = 150.76, P < 0.0001, respectively); however, co-incubation with EgCF significantly reduced LPS-stimulated TNF-α and IFN-γ levels (ANOVA: F(4, 24) = 290.00, P < 0.0001; F(4, 20) = 150.76, P < 0.0001, respectively) (Fig. 3a). On the other hand, EgCF significantly stimulated BMDMs to secrete higher levels of regulatory cytokines TGF-β and IL-10 compared with the DMEM group (ANOVA: F(4, 25) = 51.60, P < 0.0001; F(4, 25) = 309.31, P < 0.0001, respectively). The higher levels of TGF-β and IL-10 were also observed in EgCF + LPS group compared with the LPS group (ANOVA: F(4, 25) = 51.60, P < 0.0001; F(4, 25) = 309.31, P < 0.0001, respectively) (Fig. 3b). These cytokine profile data further demonstrate that EgCF promotes macrophage polarization toward M2 type and inhibits LPS-induced M1 type macrophages.

Fig. 3
figure 3

EgCF stimulated M2 type macrophage with regulatory cytokine secretions and inhabited LPS-induced M1 type cytokines. Mature BMDMs were incubated with EgCF (1 ug/ml), LPS (100 ng/ml), IL-4 (20 ng/ml), or EgCF + LPS for 24 h. a The levels of M1-related cytokines TNF-α and IFN-γ were measured in the supernatant by ELISA. b The levels of M2-related cytokines IL-10 and TGF-β were measured in the supernatant by ELISA. n = 6. The results are presented as mean ± SEM, *P < 0.05, ***P < 0.001

Full size image

EgCF improves the survival rate of septic mice

After CLP surgery, the 72-h survival status of septic mice was observed. It was found that all mice with CLP surgery without treatment died within 52 h. However, 40% of CLP mice survived for up to 72 h in the EgCF-treated group (Kaplan–Meier analysis: χ2 = 8.48, df = 1, P < 0.0036) which is even higher than those CLP mice treated with corticosteroid DXM (Kaplan–Meier analysis: χ2 = 4.25, df = 1, P < 0.0393) (Fig. 4). All mice with sham surgery with or without EgCF treatment survived for 72 h.

Fig. 4
figure 4

EgCF treatment improved the survival rate of mice with CLP-induced sepsis. After CLP or sham operation, mice were injected intraperitoneally with EgCF, DXM, or PBS. The survival rate was determined using Kaplan Meier method and compared by log-rank test. n = 10. *P < 0.05, **P < 0.01, ***P < 0.001

Full size image

EgCF significantly improves pathological outcomes in septic mice

Liver tissue pathology (Fig. 5a, b): HE staining of liver tissue sections revealed that the group of mice with sham surgery had normal liver lobule structure, large hepatocyte nuclei in a radial arrangement, and no inflammatory cell infiltration. The CLP group mice lost typical liver lobule structures infiltrated with numerous inflammatory cells. Hepatocytes were obviously edematous and disordered arrangement, and the liver pathological damage score was significantly higher compared with the sham group (ANOVA: F(4, 20) = 80.13, P < 0.0001). Hepatocyte edema, vacuolation, and inflammatory cell infiltration were significantly reduced in the CLP + EgCF and CLP + DXM groups relative to the CLP group without treatment, with significantly reduced injury scores (ANOVA: F(4, 20) = 80.13, P < 0.0001).

Fig. 5
figure 5

EgCF reduced liver, kidney, and lung injury caused by CLP-induced sepsis. a The histopathology results of liver, kidney, and lung stained with H&E. The tissue was obtained from mice 12 h after CLP and treated with EgCF, DXM, or PBS (arrows indicate inflammatory cell, shrunk glomerulus, and thickened interalveolar septum). b The pathological score comparison among different treated groups in liver, kidney, and lung tissue. The magnification × 200, scale bar = 100 µm. n = 6/group. The results are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001

Full size image

Kidney tissue pathology (Fig. 5a, b): The glomerulus structure of mice with CLP-induced sepsis was significantly shrunk and distorted, the renal tubule cell structure was damaged with renal pathological injury score significantly increased relative to the sham surgery group (ANOVA: F(4, 25) = 63.27, P < 0.0001). After being treated with EgCF, renal tissue damage was improved with reduced infiltration of inflammatory cells relative to mice without treatment (ANOVA: F(4, 25) = 63.27, P < 0.0001). Mice treated with DXM showed a similar improvement in renal pathology as the EgCF group.

Lung tissue pathology: (Fig. 5a, b): CLP-induced sepsis caused serious pathology in lung tissue with disordered alveolar structure and severe congestion and infiltration of inflammatory cells. The alveolar septum was significantly thickened. The lung pathological injury score was increased relative to the sham surgery group (ANOVA: F(4, 25) = 79.75, P < 0.0001). After being treated with EgCF, the lung pathological score was significantly improved as the group treated with DXM.

The above results showed that the EgCF protein significantly improved the pathology of septic mice, reduced tissue damage, and promoted tissue repair.

EgCF significantly improves liver and kidney function in mice

The serum levels of ALT, AST, the biomarkers for liver damage, and BUN and Cr, the biomarkers for kidney damage, were measured with a fully automated biochemical instrument. The results showed that the serum levels of ALT, AST, BUN, and Cr in mice of the CLP group were significantly higher than those in the sham group (ANOVA: F(4, 25) = 158.63, P < 0.0001; F(4, 25) = 186.20, P < 0.0001; F(4, 25) = 173.26, P < 0.0001; F(4, 25) = 91.40, P < 0.0001, respectively), indicating serious damage to liver and kidney functions. However, after being treated with EgCF or DXM, the levels of ALT, AST, BUN, and Cr were significantly reduced relative to the group without treatment (ANOVA: F(4, 25) = 158.63, P < 0.0001; F(4, 25) = 186.20, P < 0.0001; F(4, 25) = 173.26, P < 0.0001; F(4, 25) = 91.40, P < 0.0001, respectively) (Fig. 6). These results indicate that E. granulosus cyst fluid proteins confer therapeutic effects on sepsis and improve liver and kidney functions.

Fig. 6
figure 6

The levels of ALT, AST, BUN, and Cr were reduced in the sera of mice treated with EgCF. The levels of ALT, AST, BUN, and Cr were measured in the sera from mice 12 h after CLP receiving different intervention. n = 6/group. The results are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Full size image

EgCF reduces inflammatory cytokines and stimulates regulatory cytokines in septic mice

The levels of inflammatory cytokines TNF-α and IFN-γ, and regulatory cytokines TGF-β and IL-10 were measured in sera of mice with different treatment. The results showed that compared with the sham group, the serological levels of inflammatory cytokines TNF-α and IFN-γ were significantly induced in mice after CLP surgery (ANOVA: F(4, 25) = 450.64, P < 0.0001; F(4, 25) = 137.36, P < 0.0001, respectively), while the levels of regulatory cytokines TGF-β and IL-10 have no significant change. After being treated with TgCF, the levels of TNF-α and IFN-γ were significantly decreased compared with the CLP group without treatment (ANOVA: F(4, 25) = 450.64, P < 0.0001), comparable to the DXM-treated group (F(4, 25) = 137.36, P < 0.0001) (Fig. 7a). However, the serological levels of regulatory cytokines TGF-β and IL-10 were significantly stimulated after being treated with EgCF compared with the group without treatment (ANOVA: F(4, 25) = 126.49, P < 0.0001; F(4, 25) = 44.30, P < 0.0001, respectively). Treatment with DXM also significantly boosted TGF-β secretion in sera (ANOVA: F(4, 25) = 126.49, P < 0.0001; F(4, 25) = 44.30, P < 0.0001, respectively), but the increase of IL-10 was not significant (Fig. 7b).

Fig. 7
figure 7

EgCF reduced the inflammatory cytokines (TNF-α, IFN-γ) (a) and induced regulatory cytokines IL-10 and TGF-β (b) in sera of mice with CLP-induced sepsis. The cytokine levels were measured by ELISA. n = 6/group. The results are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001

Full size image

EgCF regulates macrophage polarization in liver, kidney, and lung tissues of septic mice

To further investigate whether EgCF protects septic mice by regulating macrophage polarization, RT-PCR was used to measure the expression levels of iNOS and Arg-1 mRNA in the liver, kidney, and lung tissues. The results showed that the transcriptional levels of iNOS (M1) were significantly increased in the liver, kidney, and lung tissue in CLP group mice relative to the sham group (ANOVA: F(4, 25) = 149.83, P < 0.0001; F(4, 25) = 280.13, P < 0.0001; F(4, 25) = 127.24, P < 0.0001; respectively). The Arg-1 (M2) mRNA expression level was also increased (ANOVA: F(4, 25) = 138.74, P < 0.0001, F(4, 25) = 198.50, P < 0.0001; F(4, 25) = 121.56, P < 0.0001, respectively) (Fig. 8a–c), indicating the inflammation caused by CLP-induced sepsis stimulated both M1 and M2 macrophages in these critical organs.

Fig. 8
figure 8

Treatment with EgCF inhibited iNOS mRNA expression and stimulated Arg-1 mRNA expression in the liver (a), kidney (b), and lung tissues (c) measured by quantitative PCR compared with housekeeper GAPDH. n = 6/group. The results are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001

Full size image

However, after being treated with EgCF, the sepsis-induced iNOS mRNA expression was significantly inhibited in the liver (ANOVA: F(4, 25) = 149.83, P < 0.0001), in kidney (F(4, 25) = 280.13, P < 0.0001), and in lung tissue (F(4, 25) = 127.24, P < 0.0001) compared with the CLP group without treatment. On the other hand, treatment with EgCF significantly stimulated Arg-1 mRNA expression in liver (ANOVA: F(4, 25) = 138.74, P < 0.0001), in kidney (F(4, 25) = 198.50, P < 0.0001) and in lung tissue (F(4, 25) = 121.56, P < 0.0001) compared with the group without treatment (Fig. 8a–c). Treatment with DXM also decreased the mRNA expression of iNOS and boosted the mRNA expression of Agr-1, but at a lower level compared with EgCF. The results indicate that EgCF inhibited M1 and stimulated M2 macrophages in critical organs of mice with CLP-induced sepsis.

EgCF inhibits the expression of TLR2 and MyD88 in liver, kidney, and lung tissues of septic mice

To verify whether the TLR2/MyD88 signaling pathway is involved in the therapeutic effect of EgCF in septic inflammation, the expression of TLR2 and MyD88 proteins in the liver, kidney, and lung tissue of mice was measured using western blot with specific antibodies. The results showed that TLR2 and MyD88 levels were significantly increased in the liver tissue of septic mice after CLP surgery compared with the sham group (ANOVA: F(4, 10) = 23.56, P < 0.0001; F(4, 10) = 26.47, P < 0.0001, respectively). The increased levels of TLR2 and MyD88 were also observed in kidney tissue (ANOVA: F(4, 10) = 50.64, P < 0.0001; F(4, 10) = 31.66, P < 0.0001, respectively) and in lung tissue (ANOVA: F(4, 10) = 44.01, P < 0.0001; F(4, 10) = 14.69, P < 0.0001, respectively) after CLP surgery (Fig. 9a–c), indicating that TLR2 and MyD88 are involved in the inflammation of sepsis in CLP mice. Treatment with EgCF significantly reduced the expression of TLR2 and MyD88 in the liver (ANOVA: F(4, 10) = 23.56, P < 0.0001; F(4, 10) = 26.47, P < 0.0001, respectively), kidney (F(4, 10) = 50.64, P < 0.0001; F(4, 10) = 31.66, P < 0.0001, respectively) and lung (F(4, 10) = 44.01, P < 0.0001; F(4, 10) = 14.69, P < 0.0001, respectively) of mice with CLP-induced sepsis relative to the septic mice without treatment (Fig. 9a–c). Treatment with DXM also reduced the expression of TLR2 and MyD88 in these tissues. The results indicated that the anti-inflammatory effect of EgCF on serious bacterial infections such as sepsis may take place through inhibition of the TLR2 and MyD88 inflammatory signaling pathway.

Fig. 9
figure 9

EgCF suppressed the expression of TLR-2 and MyD88 in the liver (a), kidney (b), and lung (c) of mice with CLP-induced sepsis detected by western blot with specific antibody. The β-actin was used as a control. The density ratio of TLR-2/β-actin and MyD88/β-actin are shown on the right. The results are shown as the density mean ± SEM for each group. n = 3/group. The results are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001

Full size image

Discussion

Despite the availability of appropriate antibiotic therapy and supportive care, sepsis remains the leading cause of death in patients in intensive care unit [51]. The pathogenesis of sepsis involves multifaceted interactions between the infecting microorganism and the host. Effective control of the excessive immune responses at the early stage of sepsis is crucial for patients to survive the extreme inflammation condition [52, 53].

In recent years, helminths and their derivatives have been applied to treat autoimmune or inflammatory diseases experimentally or clinically by taking advantage of their modulatory functions on host immune responses. This immunomodulation includes the induction of Th2-biased response, activation of Treg cells, or alternatively activated macrophages to avoid hyper-immune responses to the exogenous and endogenous antigens or pathogens [54,55,56]. Our previous study has demonstrated that cystatin derived from helminth Schistosoma japonicum exerted immunomodulatory effects by inhibiting pro-inflammatory cytokines and promoting regulatory cytokines IL-10 and TGF-β and improved the survival rate of sepsis in a mouse model [48]. The ES products from adult Trichinella spiralis exerted a similar therapeutic effect on sepsis and protected sepsis-caused lung injury [25]. Echinococcus granulosus infection regulates host immune responses by inducing various immune cells to express regulatory phenotypes to reshape the immune homeostasis in the host [57, 58]. Patients with cystic echinococcosis displayed significantly increased regulatory T cells and related cytokines (IL-10 and TGF-β) and decreased inflammatory Th17 cells in peripheral blood, indicating the imbalanced Th17/Treg responses may be involved in the immune evasion of the cestode larvae in the parasitized host [59]. Based on its strong immunomodulatory properties, infection with E. granulosus has been successfully used to experimentally treat colitis [38] and airway inflammation in mice [43]. The extracts from the E. granulosus hydatid-laminated layer also conferred therapeutic effect on dextran sulfate sodium-induced colitis in mice with significantly reduced mucosal damage and inflammatory responses [60]. EgCF also revealed a therapeutic effect on allergic airway inflammation in a mouse model with OVA-induced asthma [61]. Based on the above findings, we explored the therapeutic effect of EgCF on sepsis and sepsis-induced damage to critical organs in this study.

Indeed, after being treated with EgCF, the 72-h survival rate of the mice with CLP-induced sepsis significantly elevated to 40% relative to the septic mice without treatment that all died within this period (Fig. 4). Accordingly, the pathological damage to the liver, lung, and kidney tissue of mice with sepsis was also significantly improved with less inflammatory cell infiltration and reduced pathological damage score (Fig. 5) and improved liver and kidney functions with reduced serological levels of ALT, AST, BUN and Cr (Fig. 6) in EgCF-treated mice. The improved survival rate and reduced pathology in key organs in EgCF-treated mice correlated with the reduced serological levels of inflammatory cytokines TNF-α, INF-γ and increased levels of regulatory cytokines TGF-β and IL-10 (Fig. 7), indicating regulatory immune response is induced that inhibits inflammatory Th1 response. Further investigation identified the transcriptional level of arginase-1 (Arg-1) expressed mostly in M2 macrophages was significantly induced and inducible nitric oxide synthase (iNOS), the marker of M1 macrophages, was significantly inhibited in tissues of liver, lung and kidney of septic mice treated with EgCF, indicating macrophages were polarized from M1 to M2 (Fig. 8) that may contribute to the reduced inflammatory immune responses in EgCF-treated mice. However, we cannot exclude the possibility of the expression of Arg-1 and iNOS by other cells in the tissue even though Arg-1 and iNOS are the major markers of M2 and M1, respectively [62, 63] These results are consistent with the in vitro study with BMDMs incubated with EgCF that induced the M2 macrophage polarization under conditions with LPS (Fig. 2), with reduced levels of inflammatory cytokines TNF-α and INF-γ and increased regulatory cytokines TGF-β, IL-10 (Fig. 3), the similar consequence as septic mice treated with EgCF in vivo. Both in vivo and in vitro results suggest that EgCF can promote macrophage polarization toward the M2 type and inhibit LPS-induced M1 activation under septic conditions. The EgCF-induced M2 polarization may contribute to its therapeutic effect on sepsis and reduce pathology and organ damage caused by excessive inflammation under septic conditions. However, determining the changes of detailed immune cell subpopulations in the sepsis-affected organs would provide more information on the effect of EgCF on the immune responses except for M2 polarization. The passive transfer of in vitro EgCF-stimulated M2 macrophages into septic mice to measure their effect on sepsis in vivo would provide direct evidence of the M2-involved mechanism, and it has been included in our next experiment. The therapeutic effect of EgCF on the sepsis and septic inflammation storm is even stronger than DXM, an anti-inflammatory immunosuppressant commonly used in the treatment of sepsis [64,65,66]. We also observed that DXM is an immunosuppressant rather than an immunomodulator as EgCF does since the latter has a stronger effect on the induction of TGF-β and Arg-1 expression. It seems that immunomodulation of helminth-derived products plays a more important role in maintaining the immune balance and immune homeostasis than an immunosuppressant in the course of sepsis. TLRs play a key role in maintaining the delicate balance between immune tolerance and activation in the pathogenesis of sepsis [67, 68]. Studies have shown that TLR2 is a major signaling sensor for recognizing microbial infections and is involved in the pathogenesis of sepsis [24]. The TLR-mediated cascade immune response requires the participation of Myd88 as an adaptor or bridge to connect downstream inflammatory signals, which leads to the activation of nuclear transcription factor NF-κB that regulates the expression of inflammatory genes such as TNF-α, IL-1β, and IL-6 y [69]. To investigate if EgCF exerts a protective effect against sepsis by inhibiting the TLR2/MyD88-dependent inflammatory signaling pathway, the protein expression levels of TLR2 and MyD88 in the liver, kidney, and lung tissues of septic mice were examined. The levels of TLR2 and MyD88 were significantly increased in the tissues of septic mice, which was consistent with the high levels of pro-inflammatory factors in the sera of septic mice, indicating that the activation of TLR2/MyD88 signaling pathway in septic mice induced pro-inflammatory mediators. After being treated with EgCF, the expression levels of TLR2 and MyD88 in those key organs (liver, lung, and kidney) of mice with CLP-induced sepsis were significantly reduced (Fig. 9), indicating the anti-inflammatory effect of EgCF on the sepsis is through inhibiting TLR-2 and MyD88 inflammatory signaling pathway. The transcriptome data of septic tissue would provide more details of signal pathways involved in the therapeutic effect of EgCF on sepsis, it will be included in our next study.

Conclusions

The results of this study demonstrated that the cystic fluid of E. granulosus confers a therapeutic effect on sepsis by inhibiting the production of pro-inflammatory cytokines and inducing regulatory cytokines. The anti-inflammatory effect of EgCF is carried out possibly by inducing macrophage polarization from pro-inflammatory M1 to regulatory M2 phenotype to reduce excessive inflammation of sepsis and subsequent multi-organ damage. The role of EgCF in regulating macrophage polarization may be achieved by inhibiting the TLR2/MyD88 signaling pathway. EgCF contains the helminth-derived proteins without infectious larvae (protoscolices), and therefore is a safe reagent to treat inflammatory diseases; however, we are still on the way to identifying the specific components in the cystic fluid that induce immunomodulatory and regulatory functions, as therapeutic targets for autoimmune or inflammatory diseases.

Availability of data and materials

All datasets presented in this study are included in the article/supplementary material.

Abbreviations

SIRS:

Systemic inflammatory response syndrome

EgCF:

Echinococcus granulosus cyst fluid

BMDMs:

Bone marrow-derived macrophages

CLP:

Cecal ligation and puncture

CARS:

Compensatory anti-inflammatory response syndrome

TLRs:

Toll-like receptors

DXM:

Dexamethasone

ALT:

Alanine aminotransferase

AST:

Aspartate aminotransferase

BUN:

Blood urea nitrogen

ELISA:

Enzyme-linked immunosorbent assay

IL-6:

Interleukin 6

TNF-α:

Tumor necrosis factor alpha

TGF-β:

Transforming growth factor beta

IL-10:

Interleukin 10

References

  1. Rhodes A, Phillips G, Beale R, Cecconi M, Chiche JD, De Backer D, et al. The surviving sepsis campaign bundles and outcome: results from the International Multicentre Prevalence Study on Sepsis (the IMPreSS study). Intensive Care Med. 2015;41:1620–8.

    Article  PubMed  Google Scholar 

  2. Lakshmikanth CL, Jacob SP, Chaithra VH, de Castro-Faria-Neto HC, Marathe GK. Sepsis: in search of cure. Inflamm Res. 2016;65:587–602.

    Article  CAS  PubMed  Google Scholar 

  3. Novosad SA, Sapiano MR, Grigg C, Lake J, Robyn M, Dumyati G, et al. Vital signs: epidemiology of sepsis: prevalence of health care factors and opportunities for prevention. Morb Mortal Wkly Rep. 2016;65:864–9.

    Article  Google Scholar 

  4. Rello J, Valenzuela-Sánchez F, Ruiz-Rodriguez M, Moyano S. Sepsis: a review of advances in management. Adv Ther. 2017;34:2393–411.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395:200–11.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840–51.

    Article  CAS  PubMed  Google Scholar 

  7. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Chaudhry H, Zhou J, Zhong Y, Ali MM, McGuire F, Nagarkatti PS, et al. Role of cytokines as a double-edged sword in sepsis. In Vivo. 2013;27:669–84.

    CAS  PubMed  Google Scholar 

  9. Ge Y, Xu X, Liang Q, Xu Y, Huang M. α-Mangostin suppresses NLRP3 inflammasome activation via promoting autophagy in LPS-stimulated murine macrophages and protects against CLP-induced sepsis in mice. Inflamm Res. 2019;68:471–9.

    Article  CAS  PubMed  Google Scholar 

  10. Liu J, Du J, Cheng X, Zhang X, Li Y, Fu X, et al. Effect of netrin-1 anti-inflammatory factor on acute lung injury in sepsis rats. Med Sci Monit. 2019;25:7928–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Yu WK, McNeil JB, Wickersham NE, Shaver CM, Bastarache JA, Ware LB. Vascular endothelial cadherin shedding is more severe in sepsis patients with severe acute kidney injury. Crit Care. 2019;23:18.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Li H, Qiu D, Gao Q, Wang H, Sun M. Selectively activating melanocortin 4 receptor acts against rat sepsis-induced acute liver injury via HMGB1/TLR4/NF-κB signaling pathway. Chin J Cell Mol Imm. 2016;32:1055–9.

    Google Scholar 

  13. Yan J, Li S, Li S. The role of the liver in sepsis. Int Rev Immunol. 2014;33:498–510.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Almalki WH. The sepsis induced defective aggravation of immune cells: a translational science underling chemico-biological interactions from altered bioenergetics and/or cellular metabolism to organ dysfunction. Mol Cell Biochem. 2021;476:2337–44.

    Article  CAS  PubMed  Google Scholar 

  15. Kumar V. Targeting macrophage immunometabolism: dawn in the darkness of sepsis. Int Immunopharmacol. 2018;58:173–85.

    Article  CAS  PubMed  Google Scholar 

  16. Ardura JA, Rackov G, Izquierdo E, Alonso V, Gortazar AR, Escribese MM. Targeting macrophages: friends or foes in disease? Front Pharmacol. 2019;10:1255.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Karakike E, Giamarellos-Bourboulis EJ. Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis. Front Immunol. 2019;10:55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ley K. M1 means kill; M2 means heal. J Immunol. 2017;199:2191–3.

    Article  CAS  PubMed  Google Scholar 

  19. Liang X, Li T, Zhou Q, Pi S, Li Y, Chen X, et al. Mesenchymal stem cells attenuate sepsis-induced liver injury via inhibiting M1 polarization of Kupffer cells. Mol Cell Biochem. 2019;452:187–97.

    Article  CAS  PubMed  Google Scholar 

  20. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care. 2007;11:R49.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Li H, Qiu D, Yuan Y, Wang X, Wu F, Yang H, et al. Trichinella spiralis cystatin alleviates polymicrobial sepsis through activating regulatory macrophages. Int Immunopharmacol. 2022;109:108907.

    Article  CAS  PubMed  Google Scholar 

  22. Medvedev AE. Toll-like receptor polymorphisms, inflammatory and infectious diseases, allergies, and cancer. J Interferon Cytokine Res. 2013;33:467–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Jiménez-Dalmaroni MJ, Gerswhin ME, Adamopoulos IE. The critical role of toll-like receptors–From microbial recognition to autoimmunity: A comprehensive review. Autoimmun Rev. 2016;15:1–8.

    Article  PubMed  Google Scholar 

  24. Sato M, Takeuchi S, Moriya R, Kito T, Soga S, Aoyama K, et al. Novel TLR2xTLR4 bispecific antibody inhibits bacterial sepsis. Monoclon Antib Immunodiagn Immunother. 2021;40:6–10.

    Article  CAS  PubMed  Google Scholar 

  25. Evans HM, Schultz DF, Boiman AJ, McKell MC, Qualls JE, Deepe GS Jr. Restraint of fumarate accrual by HIF-1α preserves miR-27a-mediated limitation of interleukin 10 during infection of macrophages by Histoplasma capsulatum. MBio. 2021;12:e0271021.

    Article  PubMed  Google Scholar 

  26. Fan H, Wang Y, Zhao K, Su L, Deng C, Huang J, et al. Incomplete knockdown of MyD88 inhibits LPS-induced lung injury and lung fibrosis in a mouse model. Inflammation. 2023;46(6):2276–88.

    Article  CAS  PubMed  Google Scholar 

  27. Fernández A, Herrera D, Hoare A, Hernández M, Torres VA. Lipopolysaccharides from Porphyromonas endodontalis and Porphyromonas gingivalis promote angiogenesis via Toll-like-receptors 2 and 4 pathways in vitro. Int Endod J. 2023;56:1270–83.

    Article  PubMed  Google Scholar 

  28. Li H, Qiu D, Yang H, Yuan Y, Wu L, Chu L, et al. Therapeutic efficacy of excretory-secretory products of Trichinella spiralis adult worms on sepsis-induced acute lung injury in a mouse model. Front Cell Infect Microbiol. 2021;11:653843.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299:1259–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. van Riet E, Hartgers FC, Yazdanbakhsh M. Chronic helminth infections induce immunomodulation: consequences and mechanisms. Immunobiology. 2007;212:475–90.

    Article  PubMed  Google Scholar 

  31. Zaccone P, Burton OT, Cooke A. Interplay of parasite-driven immune responses and autoimmunity. Trends Parasitol. 2008;24:35–42.

    Article  CAS  PubMed  Google Scholar 

  32. Erb KJ. Can helminths or helminth-derived products be used in humans to prevent or treat allergic diseases? Trends Immunol. 2009;30:75–82.

    Article  CAS  PubMed  Google Scholar 

  33. Osada Y, Kanazawa T. Parasitic helminths: new weapons against immunological disorders. J Biomed Biotechnol. 2010;2010:743758.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Smallwood TB, Giacomin PR, Loukas A, Mulvenna JP, Clark RJ, Miles JJ. Helminth immunomodulation in autoimmune disease. Front Immunol. 2017;8:453.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Ilic N, Gruden-Movsesijan A, Sofronic-Milosavljevic L. Trichinella spiralis: shaping the immune response. Immunol Res. 2012;52:111–9.

    Article  CAS  PubMed  Google Scholar 

  36. Chua CC, Chua BHL, Zhao ZY, et al. Effect of growth factors on collagen metabolism in cultured human heart fibroblasts. Connect Tissue Res. 1991;26:271–81.

    Article  CAS  PubMed  Google Scholar 

  37. Bujak M, Ren G, Kweon HJ, et al. Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation. 2007;116:2127–38.

    Article  CAS  PubMed  Google Scholar 

  38. Levy DE, Darnell JE. STATs: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3:651–62.

    Article  CAS  PubMed  Google Scholar 

  39. Grote K, Luchtefeld M, Schieffer B. JANUS under stress-role of JAK/STAT signaling pathway in vascular diseases. Vascul Pharmacol. 2005;43:357–63.

    Article  CAS  PubMed  Google Scholar 

  40. Sun H, Wang Y. Interferon regulatory factors in heart: stress response beyond inflammation. Hypertension. 2014;63:663–4.

    Article  CAS  PubMed  Google Scholar 

  41. Li CY, Guan YY, Wu WP, Xue CZ. Progress of researches on infection with two species of Echinococcus causing human diseases in animal hosts and influencing factors. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2022;34:194–9 (Chinese).

    CAS  PubMed  Google Scholar 

  42. Khelifi L, Soufli I, Labsi M, Touil-Boukoffa C. Immune-protective effect of echinococcosis on colitis experimental model is dependent of down regulation of TNF-α and NO production. Acta Trop. 2017;166:7–15.

    Article  CAS  PubMed  Google Scholar 

  43. Wang H, Li J, Pu H, Hasan B, Ma J, Jones MK, et al. Echinococcus granulosus infection reduces airway inflammation of mice likely through enhancing IL-10 and down-regulation of IL-5 and IL-17A. Parasit Vectors. 2014;7:522.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Van Kruiningen HJ, West AB. Potential danger in the medical use of Trichuris suis for the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:515.

    Article  PubMed  Google Scholar 

  45. Schopf L, Luccioli S, Bundoc V, Justice P, Chan CC, Wetzel BJ, et al. Differential modulation of allergic eye disease by chronic and acute ascaris infection. Invest Ophthalmol Vis Sci. 2005;46:2772–80.

    Article  PubMed  Google Scholar 

  46. Zhang Y, Qi W, Jiao H, Wu C, Guo G, Ren Y, et al. Antigen B secreted by Echinococcus granulosus reduces asthma by rebalancing Th17/Treg. J Pathog Biol. 2021;16:33.

    Google Scholar 

  47. Gong W, Wen H. Sepsis induced by cecal ligation and puncture. Methods Mol Biol. 2019;1960:249–55.

    Article  CAS  PubMed  Google Scholar 

  48. Li H, Wang S, Zhan B, He W, Chu L, Qiu D, et al. Therapeutic effect of Schistosoma japonicum cystatin on bacterial sepsis in mice. Parasit Vectors. 2017;10:222.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Li YF, Xu BY, An R, Du XF, Yu K, Sun JH, et al. Protective effect of anisodamine in rats with glycerol-induced acute kidney injury. BMC Nephrol. 2019;20:223.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Wang L, Cao Y, Gorshkov B, Zhou Y, Yang Q, Xu J, et al. Ablation of endothelial Pfkfb3 protects mice from acute lung injury in LPS-induced endotoxemia. Pharmacol Res. 2019;146:104292.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Steinfelder S, O’Regan NL, Hartmann S. Diplomatic assistance: can helminth-modulated macrophages act as treatment for inflammatory disease? PLoS Pathog. 2016;12:e1005480.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Salomao R, Brunialti MK, Rapozo MM, Baggio-Zappia GL, Galanos C, Freudenberg M. Bacterial sensing, cell signaling, and modulation of the immune response during sepsis. Shock. 2012;38:227–42.

    Article  CAS  PubMed  Google Scholar 

  53. van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017;17:407–20.

    Article  PubMed  Google Scholar 

  54. Hübner MP, Layland LE, Hoerauf A. Helminths and their implication in sepsis—a new branch of their immunomodulatory behaviour? Pathog Dis. 2013;69:127–41.

    Article  PubMed  Google Scholar 

  55. Elliott DE, Weinstock JV. Helminth-host immunological interactions: prevention and control of immune-mediated diseases. Ann N Y Acad Sci. 2012;1247:83–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Radovic I, Gruden-Movsesijan A, Ilic N, Cvetkovic J, Mojsilovic S, Devic M, et al. Immunomodulatory effects of Trichinella spiralis-derived excretory-secretory antigens. Immunol Res. 2015;61:312–25.

    Article  CAS  PubMed  Google Scholar 

  57. Li W, Hu W, Xu K, Nie R, Pang M, Fan H. Progress of researches on roles of dendritic cells in immune tolerance caused by Echinococcus infections. Chin J Schi Contl. 2021;33:63.

    CAS  Google Scholar 

  58. Díaz Á. Immunology of cystic echinococcosis (hydatid disease). Br Med Bull. 2017;124:121–33.

    PubMed  Google Scholar 

  59. Tuxun T, Wang JH, Lin RY, Shan JY, Tai QW, Li T, et al. Th17/Treg imbalance in patients with liver cystic echinococcosis. Parasite Immunol. 2012;34:520–7.

    Article  CAS  PubMed  Google Scholar 

  60. Soufli I, Toumi R, Rafa H, Amri M, Labsi M, Khelifi L, et al. Crude extract of hydatid laminated layer from Echinococcus granulosus cyst attenuates mucosal intestinal damage and inflammatory responses in Dextran Sulfate Sodium induced colitis in mice. J Inflamm (Lond). 2015;12:19.

    Article  PubMed  Google Scholar 

  61. Kim HJ, Kang SA, Yong TS, Shin MH, Lee KJ, Park GM, et al. Therapeutic effects of Echinococcus granulosus cystic fluid on allergic airway inflammation. Exp Parasitol. 2019;198:63–70.

    Article  CAS  PubMed  Google Scholar 

  62. Mao K, Chen S, Chen M, Ma Y, Wang Y, Huang B, et al. Nitric oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. Cell Res. 2013;23:201–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Mishra BB, Rathinam VA, Martens GW, Martinot AJ, Kornfeld H, Fitzgerald KA, et al. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1β. Nat Immunol. 2013;14:52–60.

    Article  CAS  PubMed  Google Scholar 

  64. Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17:233–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Tsao CM, Ho ST, Chen A, Wang JJ, Li CY, Tsai SK, et al. Low-dose dexamethasone ameliorates circulatory failure and renal dysfunction in conscious rats with endotoxemia. Shock. 2004;21:484–91.

    Article  CAS  PubMed  Google Scholar 

  66. Crossland H, Constantin-Teodosiu D, Greenhaff PL, Gardiner SM. Low-dose dexamethasone prevents endotoxaemia-induced muscle protein loss and impairment of carbohydrate oxidation in rat skeletal muscle. J Physiol. 2010;588:1333–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Denning NL, Aziz M, Gurien SD, Wang P. DAMPs and NETs in sepsis. Front Immunol. 2019;10:2536.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Kumar V. Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets. Int Immunopharmacol. 2020;89:107087.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Castoldi A, Braga TT, Correa-Costa M, Aguiar CF, Bassi ÊJ, Correa-Silva R, et al. TLR2, TLR4 and the MYD88 signaling pathway are crucial for neutrophil migration in acute kidney injury induced by sepsis. PLoS ONE. 2012;7:e37584.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This project was supported by the 512 Talents Development Project of Bengbu Medical College (Nos. by51201205, by51201306), the Key Projects of Scientific Research of Anhui Provincial Health and Wellness Commission (No. AHWJ2021a005), the Support Program for Excellent Talents in Higher Educational Institutions in Anhui Province (No. gxyq2021188), and the Major Projects of Wuxi Municipal Health and Wellness Commission (No. Z202114).

Author information

Author notes

  1. Shuying Wang and Donghui Jiang contributed equally to this work.

Authors and Affiliations

  1. First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China

    Shuying Wang, Feifei Huang, Yayun Qian & Rui Zhou

  2. Anhui Key Laboratory of Infection and Immunity of Bengbu Medical College, Bengbu, 233000, China

    Shuying Wang, Feifei Huang, Yayun Qian, Huihui Li, Xiaoli Wang, Zhi Wang, Kaigui Wang, Liang Chu & Xiaodi Yang

  3. Department of Pediatrics, Anqing First People’s Hospital of Anhui Medical University, Anqing, 246000, China

    Shuying Wang & Meitao Qi

  4. Department of Critical Care Medicine, Affiliated Hospital of Jiangnan University, Wuxi, 214122, China

    Donghui Jiang, Yin Wang & Pengfei Du

  5. National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, 77030, USA

    Bin Zhan

  6. Second Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China

    Liang Chu

Authors
  1. Shuying Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donghui Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Feifei Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yayun Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Meitao Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Huihui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaoli Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kaigui Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Pengfei Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Bin Zhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Rui Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Liang Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Xiaodi Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XDY, LC, and SYW conceived and designed the study; SYW, DHJ, FFH, YYQ, HHL, XLW, ZW, and KGW performed the experiments; MTQ, HHL, XLW, YW, and PFD analyzed the data; SYW and DHJ wrote the manuscript, BZ, RZ, LC, and XDY critically revised the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Liang Chu or Xiaodi Yang.

Ethics declarations

Ethics approval and consent to participate

The animal study was reviewed and approved by the Animal Care and Use Committee of Bengbu Medical College (approval no. LAEC-2022-413).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, S., Jiang, D., Huang, F. et al. Therapeutic effect of Echinococcus granulosus cyst fluid on bacterial sepsis in mice. Parasites Vectors 16, 450 (2023). https://doi.org/10.1186/s13071-023-06021-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13071-023-06021-7

Keywords

Parasites & Vectors

ISSN: 1756-3305

Contact us